Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency

AIDS Research and Human Retroviruses

Volumn 14, Issue 6, 1998, Pages 483-490

  Tsoukas, Christos M ^a   Raboud, Janet ^b   Bernard, Nicole F ^a   Montaner, Julio S G ^b   Gill, M John ^c   Rachlis, Anita ^d   Fong, Ignatius W ^e   Schlech, Walter ^f   Djurdjev, Ognjenka ^b   Freedman, John ^e   Thomas, Réjean ^g   Lafrenière, René ^c   Wainberg, Mark A ^h   Cassol, Sharon ^b   O'Shaughnessy, Michael ^b   Todd, John ⁱ   Volvovitz, Frank ^h   Smith, Gale E ^j  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g Clinique l'Actuel   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j MicroGeneSys Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ACTIVE IMMUNIZATION; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VIREMIA;

EID: 0032502697     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.483     Document Type: Article

References (45)

1. Daar ES, Moudgil T, Meyer RD, and Ho DD: Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-967.
2. Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, and Shaw GM: High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-960.
3. Tindall B and Cooper DA: Primary HIV infection: Host responses and intervention strategies. AIDS 1991;5:1-14.
4. Pantaleo G and Fauci AS: New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995;13:487-512.
5. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowski W, et al: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:4650-4655.
6. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
8. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, and Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 1993;362:355-358.
9. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, and Haase AT: Massive covert infection of helper T Lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 1993;362:359-362.
10. Robert-Guroff M, Brown M, and Gallo RC: HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (London) 1985;316:72-74.
11. Weiss RA, Clapham PR, Cheingsong-Popov R, Dalgleish AG, Came CA, Weller IVD, and Tedder RS: Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (London) 1985;316:69-72.
12. Lyerly HK, Reed DL, Matthews TJ, Langlois AJ, Ahearne PM, Petteway SR, and Weinhold KL: Anti-gp120 antibodies from HIV seropositive individuals mediated broadly reactive anti-HIV ADCC: AIDS Res Hum Retroviruses 1987;3:409-422.
13. Walker BD, Chakrabarti S, Moss M, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC, Hirsch MS, and Schooley RT: HIV-specific cytotoxic T-lymphocytes in seropositive individuals. Nature (London) 1987;328:345-348.
14. Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaun JJ, Gallo RC, Shearer GM, and Zagury D: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature (London) 1988;334: 706-708.
15. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, and Shearer GM: Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-765.
16. Walker C, Moody D, Stites D, and Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
17. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
18. Baler M, Werner A, Bannert N, Metzner K, and Kurth R: HIV suppression by IL-16. Nature (London) 1995;378:563.
19. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, Vilmer E, Michel F, Mayaud C, Autran B, and Plata F: Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989;142:452-462.
20. Klein M, van Baalen C, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IPM, Eeftinck-Schattenkerk J-KM, Osterhaus ADME, Schuitemaker H, and Miedema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
21. Burke RL: Contemporary approaches to vaccination against herpes simplex virus. Curr Topics Microbiol Immunol 1992;179: 137-158.
22. Convit J, Ulrich M, Fernandez CT, Tapia FJ, Caceres-Dittmar G, Castes M, and Rondon AJ: The clinical and immunological spectrum of American cutaneous Leishmaniasis. Trans R Soc Trop Med Hygiene 1993;87:444-448.
23. Stanford SL: The history and future of vaccination and immunotherapy for leprosy. Trop Geograph Med 1994;46:93-109.
24. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, and Brechet C: Vaccination against hepatitis B virus: An efficient immunoptherapy against hepatitis B multiplication. CR Acad Sci 1993;316: 688-691.
25. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, and Burke DS: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with human immunodeficiency virus infection. N Engl J Med 1991;324:1677-1684.
26. Tsoukas CM, Bernard NF, Sampalis J, Wainberg M, Cassol S, O'Shaughnessy M, Volvovitz F, and Smith GE: Specific immunotherapy with VaxSyn: A phase I/II study of the safety of recombinant gp160 vaccine in human immunodeficiency virus-infected individuals. Immunol Infect Dis 1995;5:218-223.
27. Wahren B, Bratt G, Persson C, Leven B, Hinkula J, Gilljam G, Nordlund S, Eriksson L, Volvovitz F, Broliden PA, and Sandström E: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994;7:220-229.
28. Trauger RJ, Ferre F, Daigle AE, Jensen FC. Moss RB, Mueller SH, Richieri SP, Slade HB, and Carlo DJ: Effect of immunization with inactivated rgp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994;169:1256-1264.
29. Eron JJ Jr, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, and Twaddell T: Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996;348:1547-1551.
30. Dolin R, Graham BS, Greenberg SB, Tacket C, Belshe R, Clements ML, Mithun K, Gorse JG, Horgan B, Atmer RL, Karzon D, Bonnez W, Fernie BF, Stablein D, Smith G, Koff W, and the NIAID AIDS Vaccine Clinical Trials Network: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-127.
31. Stanhope PE, Liu AY, Pavlat W, Pitha PM, Clements ML, and Siliciano RF: An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol 1993;150:4672-4686.
32. Orentas RJ, Hildreth JKE, Obah E, Polydefkis M, Smith GE, Clements ML, and Siliciano RF: An HIV envelope protein vaccine induces CD4+ human cytolytic T cells active against HIV-infected cells. Science 1990;248:1234-1237.
33. Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, and Reichman RC: Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991;163: 448-453.
34. Vasudevachari MB, Uffelman KW, Kovacs J, Yeh C-K, Lane HC, and Salzman NP: Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160. J Acquir Immune Defic Syndr 1992;5:817-821.
35. Kundu SK and Merigan T: Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes. AIDS 1992;6:643-649.
36. Kundu SK, Katzenberg D, Mosese LE, and Merigan TC: Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected patients given recombinant gp160 vaccine. Proc Natl Acad Sci USA 1992;89:11204-11208.
37. Schawaller M, Smith GE, Skehel JJ, and Wiley DC: Studies of cross linking reagents on the oligomeric structure of the env glycoprotein of HIV. Virology 1989;172:367-369.
38. National Institutes of Health: Division of AIDS, National Institutes of Allergy and Infectious Diseases American Clinical Trials Group (ACTG) Virology Manual for HIV Laboratories. National Institutes of Health Publication No. 943828. National Institutes of Health, Bethesda, Maryland, 1994.
39. Centres for Disease Control: Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMMWR 1986;35:334-339.
40. Tsoukas CM, Raboud J, Bernard N, Djurdjev O, Cassol S, Chernoff D, Fong I, Freedman J, Gill J, Goldberg E, Lafreniere R, Lee S, Montaner J, Poon M-C, Rachlis A, Schlech W, Smith G, Szabo J, Todd J, Thomas R, and Volvovitz F: Therapeutic vaccination: A randomised controlled study of the effect of rgp160 on progression of immune deficiency and viral burden. In: Third International Congress on Drug Therapy in HIV Infection, Birmingham, UK, November 3-7, 1996.
41. Tayler JMG, Tan SJ, Detels R, and Giorgi J: Applications of a computer simulation model of the natural history of CD4 T-cell number in HIV infected individuals AIDS 1992;5:159-167.
42. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderley WG, Allan JD, Wong B, Merigan TC, McAuliffe VJ, Hyslop NE, Rhame FS, Balfour JJ Jr, Spector SA, Volberding P, Pettinelli C, and Johnson J: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112:727-737.
43. Goeddert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC, Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MC, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, and Gail MH: A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989;321:1141-1148.
44. Hoffmann GW, Kion TA, and Grant MD: An idiotypic network model of AIDS immunopathogenesis. Proc Natl Acad Sci USA 1991;88:3060-3064.
45. Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead SB, and Burke DS: Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 1993;9:1175-1183.